Ratings for DexCom (NASDAQ:DXCM) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ...
In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...
In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the ...
Though it received a green light in Europe this past March, Dexcom will resubmit the G7 CGM's software for FDA review after making changes to how it delivers glucose alerts. (Dexcom) Diabetes tracker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results